Domzalski David's Insider Trades & SAST Disclosures
Domzalski David's most recent trade in VYNE Therapeutics Inc was a trade of 8,681 Common Stock done at an average price of $0.8 . Disclosure was reported to the exchange on June 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Domzalski David.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| VYNE Therapeutics Inc | David Domzalski | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.81 per share. | 02 Jun 2025 | 8,681 | 454,244 (1%) | 0% | 0.8 | 7,032 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.58 per share. | 31 Mar 2025 | 30,498 | 445,563 (1%) | 0% | 1.6 | 48,187 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 730,000 | 730,000 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | Domzalski David | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.35 per share. | 31 Dec 2024 | 24,536 | 476,061 (1%) | 0% | 3.4 | 82,196 | Common Stock |
| VYNE Therapeutics Inc | Domzalski David | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 2.10 per share. | 30 Nov 2024 | 3,901 | 500,597 (2%) | 0% | 2.1 | 8,192 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.88 per share. | 30 Sep 2024 | 685 | 496,696 (2%) | 0% | 1.9 | 1,288 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.92 per share. | 01 Jul 2024 | 935 | 497,654 (2%) | 0% | 1.9 | 1,795 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 2.16 per share. | 31 May 2024 | 4,429 | 498,589 (2%) | 0% | 2.2 | 9,562 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 01 Apr 2024 | 1,004 | 494,160 (2%) | 0% | 3.1 | 3,092 | Common Stock |
| VYNE Therapeutics Inc | Domzalski David | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 225,000 | 496,168 (2%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.28 per share. | 01 Jan 2024 | 1,004 | 495,164 (2%) | 0% | 2.3 | 2,289 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 225,000 | 271,168 (1%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Domzalski David | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.81 per share. | 30 Nov 2023 | 2,284 | 46,168 (0%) | 0% | 2.8 | 6,426 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 30 Jun 2023 | 981 | 52,433 (0%) | 0% | 4.1 | 4,022 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.46 per share. | 31 May 2023 | 2,766 | 53,414 (0%) | 0% | 3.5 | 9,560 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 31 Mar 2023 | 2,734 | 50,648 (0%) | 0% | 3.1 | 8,421 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.15 per share. | 31 Dec 2022 | 10,685 | 1,064,290 (4%) | 0% | 0.2 | 1,603 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.20 per share. | 30 Nov 2022 | 34,705 | 1,074,975 (4%) | 0% | 0.2 | 6,861 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.22 per share. | 30 Sep 2022 | 10,683 | 1,040,270 (4%) | 0% | 0.2 | 2,382 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 30 Jun 2022 | 10,683 | 1,050,953 (4%) | 0% | 0.4 | 4,156 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.35 per share. | 31 May 2022 | 11,887 | 1,061,636 (4%) | 0% | 0.3 | 4,116 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.65 per share. | 31 Mar 2022 | 23,186 | 1,049,749 (4%) | 0% | 0.7 | 15,071 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 312,303 | 312,303 | - | - | Stock Options | |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 312,302 | 1,072,935 (4%) | 1% | 0 | Common Stock | |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.88 per share. | 30 Nov 2021 | 4,705 | 767,520 (3%) | 0% | 0.9 | 4,119 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 30 Sep 2021 | 13,096 | 762,815 (3%) | 0% | 1.4 | 18,203 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2021 | 320,313 | 320,313 | - | - | Stock Options | |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2021 | 320,312 | 775,911 (3%) | 1% | 0 | Common Stock | |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 30 Jun 2021 | 18,859 | 455,599 (1%) | 0% | 3.5 | 66,195 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.36 per share. | 28 May 2021 | 941 | 474,458 (1%) | 0% | 3.4 | 3,159 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.84 per share. | 31 Mar 2021 | 6,316 | 473,517 (1%) | 0% | 6.8 | 43,201 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 358,750 | 358,750 | - | - | Stock Options | |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 153,750 | 479,833 (1%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.44 per share. | 30 Nov 2020 | 4,263 | 1,313,990 (5%) | 0% | 1.4 | 6,160 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.66 per share. | 30 Sep 2020 | 6,239 | 1,309,727 (5%) | 0% | 1.7 | 10,357 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.38 per share. | 08 Sep 2020 | 75,000 | 1,315,966 (5%) | 0% | 1.4 | 103,568 | Common Stock |
| VYNE Therapeutics Inc | David Domzalski | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.73 per share. | 30 Jun 2020 | 6,239 | 1,240,966 (5%) | 0% | 1.7 | 10,793 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges